| Type: | mab |
| Source: | u |
| Target: | IGF1R, ErbB3 |
| Cas Number: | 1509928-04-4 |
| Atc Prefix: | none |
| Chemspiderid: | none |
| C: | 8802 |
| H: | 13532 |
| N: | 2392 |
| O: | 2796 |
| S: | 58 |
| Unii: | XLR461MD3M |
| Kegg: | D10943 |
| Synonyms: | MM-141 |
Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.[1]
It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer.[2]